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http://www.molecular-cancer.com/content/13/1/194RESEARCH Open AccessAntitumor activity of the ERK inhibitor SCH722984
against BRAF mutant, NRAS mutant and wild-type
melanoma
Deborah JL Wong1†, Lidia Robert1†, Mohammad S Atefi1, Amanda Lassen1, Geetha Avarappatt1,7,
Michael Cerniglia1, Earl Avramis1, Jennifer Tsoi2, David Foulad1, Thomas G Graeber2, Begonya Comin-Anduix3,4,
Ahmed Samatar5, Roger S Lo2,4,6 and Antoni Ribas1,2,3,4*Abstract
Background: In melanoma, dysregulation of the MAPK pathway, usually via BRAFV600 or NRASQ61 somatic mutations,
leads to constitutive ERK signaling. While BRAF inhibitors are initially effective for BRAF-mutant melanoma, no
FDA-approved targeted therapies exist for BRAF-inhibitor-resistant BRAFV600, NRAS mutant, or wild-type melanoma.
Methods: The 50% inhibitory concentration (IC50) of SCH772984, a novel inhibitor of ERK1/2, was determined in a
panel of 50 melanoma cell lines. Effects on MAPK and AKT signaling by western blotting and cell cycle by flow
cytometry were determined.
Results: Sensitivity fell into three groups: sensitive, 50% inhibitory concentration (IC50) < 1 μM; intermediately
sensitive, IC50 1-2 μM; and resistant, >2 μM. Fifteen of 21 (71%) BRAF mutants, including 4 with innate vemurafenib
resistance, were sensitive to SCH772984. All three (100%) BRAF/NRAS double mutants, 11 of 14 (78%) NRAS mutants
and 5 of 7 (71%) wild-type melanomas were sensitive. Among BRAFV600 mutants with in vitro acquired resistance to
vemurafenib, those with MAPK pathway reactivation as the mechanism of resistance were sensitive to SCH772984.
SCH772984 caused G1 arrest and induced apoptosis.
Conclusions: Combining vemurafenib and SCH722984 in BRAF mutant melanoma was synergistic in a majority of
cell lines and significantly delayed the onset of acquired resistance in long term in vitro assays. Therefore,
SCH772984 may be clinically applicable as a treatment for non-BRAF mutant melanoma or in BRAF-mutant
melanoma with innate or acquired resistance, alone or in combination with BRAF inhibitors.
Keywords: ERK inhibitor, BRAF inhibitor, Melanoma, Targeted therapy, Acquired resistanceBackground
Currently, targeted therapy for metastatic melanoma hinges
on determining BRAF mutational status. Approximately
50% of all melanomas contain an activating BRAFV600,
a serine-threonine kinase which functions as an oncogenic
driver. This constitutively activates the MAPK pathway
via sequential phosphorylation of MEK and then ERK.
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unless otherwise stated.selectively inhibit BRAFV600, leading to improvements in
both progression free survival and overall survival for
patients with this disease [1-3]. However, BRAF inhibition
is not effective in the remaining 50% of BRAF wild-type
melanoma, including NRASQ61 melanoma. Indeed, treat-
ment of non-BRAF mutant cells with dabrafenib or vemur-
afenib would result in paradoxical activation of the MAPK
pathway, mediated by CRAF [4,5].
For BRAFV600 mutant melanoma, initial response
rate to BRAF inhibitors (BRAFi) is beyond 50%, though
median duration of response is only 6-7 months. Resistance
to BRAFi has been reported to occur via MAPK-dependent
and -independent mechanisms. Reported MAPK-dependent
mechanisms include secondary mutations in NRAS [6] ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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BRAF gene amplification [10] or development of BRAFV600E
splice variants [11]. MAPK-independent mechanisms of
acquired resistance also occur, through the upregulation
of receptor tyrosine kinases (RTKs), such as the platelet-
derived growth factor beta (PDGFRβ) [6], or the insulin
growth factor receptor 1 (IGF1R), or deletions of PTEN
[12]. These all lead primarily to enhanced PI3K/AKT/
mTOR signaling rather than reactivation of the MAPK
pathway. These mechanisms of acquired resistance are
generally mutually exclusive and predict for susceptibil-
ity to inhibition with other targeted therapies in vitro;
cell lines with secondary NRASQ61 mutations remain
sensitive to a MEK inhibitor [13] (MEKi), while cell
lines displaying RTK upregulation are cross-resistant
to a MEKi but sensitive to a PI3K, AKT or mTOR in-
hibitor in combination with vemurafenib [14,15].
Combining BRAFi and MEKi delays the development
of resistance in vitro compared to treatment with BRAFi
or MEKi alone [16,17]. Likewise, a phase I/II clinical trial
of dabrafenib and trametinib in BRAFV600 mutant meta-
static melanoma resulted in progression-free survival of
9.4 months compared to 5.8 months in patients treated
with dabrafenib alone. Response rates for the combin-
ation and dabrafenib alone treatments were 76% and
54%, respectively [2]. However, resistance develops both
in vitro and in vivo to this combination, thus additional
treatments for melanoma are needed.
MEKi may have clinical activity in NRAS mutant
melanoma. In vitro, inhibition occurs at nanomolar
concentrations [13]. Resistance to MEKi is MAPK
dependent [18-20]. In vivo, MEK inhibitors are effect-
ive in NRAS-mutated melanoma, though therapeutic
activity is modest compared to BRAFi in BRAF mutant
melanoma [21,22].
Inhibition of ERK1 and ERK2 (ERK1/2) is a promising
strategy to address both innate and acquired resistance
to BRAFi and MEKi, regardless of the upstream mech-
anism(s) of MAPK reactivation. ERK1/2, the main down-
stream effectors of the MAPK pathway, activate proteins
such as RSK and transcription factors needed to regulate
cellular growth and survival [23,24] such as cyclin D1,
which promotes progression through the G1 phase of the
cell cycle [25]. There is extensive crosstalk between MAPK
and PI3K/AKT pathways [26]. While some data indicate
that activation of the MAPK pathway may decrease AKT
signaling [27], cross-activation of the PI3K/AKT/mTOR
pathway has been shown to be mediated directly by
activation of ERK or via activation of RSK, leading to
activation of mTORC1 [28,29]. Cross-inhibition versus
cross-activation may vary based on cellular context or
be timing dependent. Therefore, inhibiting ERK may
result in inhibition of the oncogenic MAPK signaling
in most melanomas, with added effects of partiallyinhibiting proliferative signals through the PI3K/AKT/
mTOR pathway.
SCH772984 is a potent, ATP competitive and non-
competitive inhibitor of ERK 1/2, with additional allosteric
properties that inhibit ERK activation/phosphorylation by
MEK [30]. It has been shown to be effective at nanomolar
concentrations in multiple tumor cell lines including breast,
colon, and melanoma [30]. SCH772984 specificity for
ERK1/2 kinases occurs at concentrations up to 1 μM
and it inhibits phosphorylation of downstream ERK
targets such as RSK. Given its specificity for ERK and
the potential for ERK inhibition to inhibit both MAPK
and PI3K/AKT pathways, we evaluated the susceptibility
of wild-type, mutant BRAF- or NRAS-melanoma, and
BRAF-mutant melanoma with acquired BRAFi resist-
ance. We also tested the effect of combined BRAF and
ERK inhibition on BRAF-mutant melanoma in short-term
and long-term cultures to determine if combination therapy
would result in improved inhibition or delay the develop-
ment of resistance in vitro.
Results
BRAF-mutant melanoma cell lines are sensitive to
ERK inhibition
Twenty-one melanoma cell lines containing mutations
in the BRAF gene were evaluated to determine sensitiv-
ity to SCH772984 (ERKi). As a comparison, sensitivity
to vemurafenib was also determined. BRAFV600E was
the most frequently observed BRAF mutation, present in
17 of 21 cell lines. M381 contains BRAFV600R substitution,
M414 contains BRAFV600K, M417 contains BRAFG466E and
M420 contains BRAFL597S mutation. Among the 21 cell
lines, sensitivity to vemurafenib or SCH-772984 fell into
3 groups: highly sensitive (50% inhibitory concentration,
IC50 < 1 μM), intermediate sensitivity (IC50 1–2 μM)
and resistant (IC50 > 2 μM). 15 cell lines were highly
sensitive to SCH-772984 with IC50 less than or equal to
1 μM. Of the 12 cell lines highly sensitive to vemurafenib,
all contain BRAFV600E and were also sensitive to SCH-
772984. Interestingly, M399, M414, M308, and M409 were
sensitive to SCH-772984 but only intermediately sensitive
(M399, M409 and M414) or resistant (M308) to vemurafe-
nib. With the exception of M414, all non-V600E mutants
were resistant to both vemurafenib and SCH772984
(Figure 1A). As a comparison, sensitivity to the MEKi
trametinib segregated all cell lines into three different
groups: highly sensitive (IC50 < 2nM), intermediately
sensitive (IC50 2-30nM) and resistant (IC50 > 30 nM)
(Additional file 1: Figure S1). In general, cell lines sensitive
to SCH772984 were also sensitive to trametinib.
We next determined a time-course of SCH772984 on
MAPK and PI3K/AKT pathway signaling for M238, a
SCH772984-sensitive BRAFV600E-mutant melanoma cell
line and M233, a SCH772984-resistant BRAFV600E-mutant
Figure 1 Effect of SCH-722984 on BRAF-mutant melanoma cell lines. A. IC50 (nM). 21 BRAF-mutant melanoma cell lines were exposed to
0–10 μM SCH-722984 (black bars) or vemurafenib (grey bars) and cell viability determined by ATP-based bioluminescence assay. Results are the
mean of three experiments, performed in duplicates (n = 6). Error bars are standard deviation. Non-V600E substitutions are denoted in the bar
graph for each corresponding cell line (M420, BRAFL597S; M381, BRAFV600R , M417, BRAFG466E, M414, BRAFV600K). Bar at 1 μM denotes threshold
between sensitive and intermediate. Resistant cell lines have IC50 higher than 2 μM. B. Timecourse effects of SCH722984 on the MAPK signaling.
SCH722984-sensitive M238, SCH722984-resistant M233, were treated in a timecourse manner with 500nM SCH722984 at 1, 2, 6, 12, 24 and 48 hours
compared to DMSO as solvent control (C). Phosphorylated or total MEK, ERK1/2, RSK, AKT, or beta-actin as loading control were determined by
western blot analysis. C. Effects of SCH722984 on the MAPK signaling at 24 hours. SCH722984-sensitive M262, SCH722984-resistant M381,
SCH722984-intermediately sensitive M409 cells were treated for 24 h with DMSO as solvent control (−) or 500 nM SCH722984 (+).
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http://www.molecular-cancer.com/content/13/1/194melanoma cell line (Figure 1B). For both M233 and M238,
treatment with 500nM SCH772984 inhibited pRSK, a
known ERK1/2 downstream target, as well as pERK1/2
itself. For the resistant M233, the MAPK inhibition was
strong as early as 1 hour post treatment, with decreased
pERK and near-complete disappearance of pRSK. However,
between 12 and 24 hours we observe a rebound in the
pathway with a return to baseline pERK1/2 levels and an
induction in pMEK above baseline levels by 24 hours. Little
change in pAKT was seen at any timepoint up to 24 hours,
though a mild induction was seen at 48 hours. For the
sensitive M238, pRSK levels also decreased as early as
1 hour and levels continued to decrease thereafter. Mean-
while, pERK1/2 remained suppressed through 24 hours.
By 48 hours, pERK1/2 levels increased, though at reducedlevels compared to baseline. Concomitant with this, pMEK
levels remained unchanged until 24 hours and increased
further by 48 hours. Regarding pAKT, an early induction at
1 hour occurred, followed by decreases thereafter though
never becoming completely suppressed even at 48 hours.
In both cell lines, pRSK remained blocked at all timepoints,
demonstrating ongoing, potent inhibition of ERK1/2 activ-
ity by SCH772984. These data supports that the distinction
between sensitive and resistant cell lines could be best
made based on pERK recovery at 24 hours, as recovery of
the feedback loop that restores MAPK activity occurred by
24 hours in the resistant cell line whereas the sensitive cell
line required longer than 24 hours. Therefore, for subse-
quent analyses, we selected 24 hours as the optimal time-
point to compare signaling in our cell lines.
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resentative of the different sensitivity groups to SCH772984
were profiled in terms of downstream signaling inhibition
at 24 hours: a highly sensitive cell line (M262, BRAFV600E),
an intermediately sensitive cell line (M409, BRAFV600E),
and a resistant cell line (M381, BRAFV600R). For M262,
treatment with SCH772984 resulted in disappearance of
pRSK, disappearance of pERK1/2, decrease in pAKT, and
slight induction of pMEK at 24 hours. M409 had a similar
cell signaling profile as M262, consistent with its modest
sensitivity. For M381induction of pMEK and pERK1/2 were
seen with no change in pRSK at 24 h.
To determine the effect of SCH772984 on the PI3K/AKT
pathway, we first evaluated the baseline pAKT levels for a
group of cell lines (Additional file 2: Figure S2). We found
a weak correlation with the activity of the PI3K/AKT
pathway and sensitivity to SCH772984 for BRAF mutants.
For example, M238 and M409 are two clear examples of
cell lines with low levels of pAKT related to sensitivity
to SCH772984. For both of them, ERK inhibition with
SCH772984 was accompanied by an upregulation of
pAKT levels even at 24 hours treatment (Figure 1B). M233
was among the resistant BRAFV600E melanoma cell lines,
which appeared to have increased pAKT at baseline com-
pared to other BRAF mutant cell lines. Consistent with this,
M233 is a PTEN null cell line and has a concomitant
AKT1 amplification [31]. After treatment with SCH772984
(Figure 1B), these levels stay constant, indicating that dual
inhibition with SCH772984 and AKT/mTOR inhibitors
may be a useful strategy. In contrast, M262 is an AKT1
amplified cell line [31] with high sensitivity to SCH772984
and vemurafenib. Treatment of M262 with SCH772984 re-
duced both pERK1/2 and pAKT levels, indicating blockade
of the MAPK pathway and PI3K/AKT pathway at the
same time (Figure 1C). In general, the presence of AKT1
or AKT2 amplification did not preclude sensitivity to
SCH772984, as three of five such cell lines were highly
sensitive to SCH772984 (M229, M249, and M262), one
was intermediately sensitive (M255), and M233 and
M308 were resistant (Figure 1A).
Given high baseline pAKT levels were seen in some
cells resistant to ERK inhibition (Additional file 2: Figure S2)
and the persistence of pAKT activity with SCH722984 treat-
ment, we evaluated the effect of SCH772984 in combination
with the AKT inhibitor MK-2206 or the mTOR inhibitor
MK-8669. The addition of either the AKTi or mTORi
always resulted in more potent cell growth inhibition com-
pared to ERKi alone (Additional file 3: Figures S3A and 3B).
Combining SCH772984 with the mTOR inhibitor MK-8669
was particularly synergistic. For BRAF-mutant cell line
M233, both combinations resulted in more complete
decrease in pERK compared to treatment with SCH772984
alone. Despite the improved inhibition of the MAPK
pathway, the levels of pAKT were largely unaffected bythe addition of MK-2206 or MK-8669 (Additional file 3:
Figure S3C).
Potent SCH772984-mediated ERK inhibition in BRAF-wild
type melanoma cell lines
Currently, there is no effective targeted therapy for
BRAF wild-type melanoma, which comprises 50% of
all melanomas. Fourteen NRAS mutant melanoma and
seven cells lines with wild-type BRAF and NRAS were
evaluated for SCH772984 sensitivity. As shown in
Figure 2A, while all NRAS-mutant cell lines were re-
sistant to vemurafenib, 11 of 14 were highly sensitive
to SCH772984 (IC50 < 1 μM). Across the 11 NRAS sen-
sitive cell lines, two of them were Q61L (M296 and
M311), four were Q61K (M408, Sbcl2, WM1366, M245
and M244), one was Q61H (M243) and three were
Q61R (SKMEL173, M296 and M412a). Interestingly,
the three cell lines with IC50 > 1uM (M202, M207 and
M318) were exclusively NRAS Q61L mutated. Sensitiv-
ity to trametinib are shown in Additional file 4: Figures
S4A and 4B for NRAS-mutant and wild-type melan-
oma cell lines, respectively. Consistent with the profile
for sensitive cell lines, treatment with SCH772984 for
the sensitive M408 resulted in decreased pRSK, dis-
appearance of pERK1/2, and slight induction of pMEK,
with no change in total RSK, MEK, ERK 1/2, or AKT.
For the resistant M202, a modest induction of pMEK
with some decrease in pERK and pRSK was observed
at 24 hours (Figure 2B). Treatment with SCH772984
resulted in upregulation of pAKT levels for M408 and
WM1366 (Additional file 3: Figure S3C). Consistent
with the synergistic growth inhibition seen with com-
bining SCH772984 and either MK-2206 or MK-8669,
pAKT levels were abrogated with the addition of MK-
2206 (AKT inhibitor) and MK-8669 (mTOR inhibitor)
(Additional file 3: Figure S3A-C).
For BRAF and NRAS wild-type melanoma cell lines,
all seven were sensitive to ERK inhibition, with six
of seven highly sensitive to SCH772984 (Figure 3A),
including M418, which is a KRASG12A mutant. Con-
sistent with this, treatment with SCH772984 in the
highly sensitive M285 line resulted in complete dis-
appearance of pRSK, decreased pERK1/2 and induc-
tion of pMEK. M257, which is intermediately sensitive
to SCH722984, had near-complete disappearance of
pRSK, though pERK1/2 was slightly induced at
24 hours. Phospho-MEK was also induced in treated
cells. No changes in pAKT with SCH772984 were seen
in either M285 or M257 (Figure 3B). These data indi-
cate that SCH772984 may be effective against a major-
ity of BRAF wild-type cell lines including NRAS
mutants and BRAF/NRAS wild-type melanoma cell
lines which remain dependent on the MAPK pathway
for continued growth.
Figure 2 Susceptibility of NRAS-mutant melanoma cell lines to SCH-722984. A. IC50 (nM). Melanoma cell lines containing mutations in NRAS
were exposed to 0–10 μM SCH-722984 (black bars) or vemurafenib (grey bars), and the cell viability determined. Results are the mean of three
experiments, performed in duplicate (n = 6). Error bars are standard deviation. Bar at 1 μM denotes threshold between sensitive and intermediate.
Resistant cell lines have IC50 higher than 2 μM. B. Effects of SCH722984 on MAPK signaling. SCH722984-resistant M202 and SCH722984-sensitive
M408 were treated for 24 h with DMSO as solvent control (−) or 500 nM SCH722984 (+). Phosphorylated or total MEK, ERK 1/2, RSK, AKT or
beta-actin as loading control were determined by western blot analysis.
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acquired vemurafenib-resistance
The IC50 of SCH722984 or vemurafenib was next de-
termined in eight BRAF-mutant vemurafenib-resistant
melanoma cell lines (Figure 4A). M376 and M398, two
BRAF/NRAS double mutant cell lines derived from the
same patient tumors, were highly sensitive to SCH722984,
despite high resistance to vemurafenib. M376 is a
spontaneously arising double mutant, whereas M398
was established from tumor from the same patientupon progression on vemurafenib. Similar to their iso-
genic parental cell lines, potent growth inhibition with
SCH772984 was also seen for three BRAFV600E mutant
melanoma cell lines with in vitro-derived vemurafenib re-
sistance (polyclonal population): M395AR, M397AR, and
M249AR4. Previously data demonstrated that these cell
lines reactivate the MAPK pathway via generation of BRAF
splice variants (M395AR and M397AR) [7,24], or via sec-
ondary NRAS mutation (M249AR4) [6]. In contrast,
M229AR9, M238AR2 and M409AR1 remained highly
Figure 3 Susceptibility of BRAF/NRAS wild-type melanoma to SCH-722984. A. IC50 (nM). Cells were treated with 0–10 μM SCH-722984
(black bars) or vemurafenib (grey bars) and cell viability determined by ATP-based bioluminescence assay. Results are the mean of duplicate
experiments, performed in triplicate (n = 6). Error bars are standard deviation. Bar at 1 μM denotes threshold between sensitive and intermediate.
Resistant cell lines have IC50 higher than 2 μM. B. Effects of SCH722984 on MAPK signaling. SCH-722984-resistant M257 and SCH-722984-sensitive
M285, were treated for 24 h with DMSO (−) or 500 nM SCH722984 (+). Phosphorylated or total MEK, ERK 1/2, RSK, AKT or beta-actin as loading
control were determined by western blot analysis.
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and M238AR2 upregulation of RTK is the mechanism of
vemurafenib resistance [6]. The mechanism of resistance for
M409AR is unknown at this time, and studies are ongoing
to delineate the mechanism underlying BRAFi-resistance.
Consistent with the signaling for other sensitive cell
lines, all three BRAF/NRAS double mutants (M376,
M398, M249AR4) displayed decreased pRSK and pERK1/2
at 24 hours with no detectable change in pMEK. In thepaired parental and acquired-resistance cell lines, treatment
of the parental cell lines (M397, M249, M229, M238 and
M409) with SCH722984 resulted in disappearance of pRSK,
decrease in pERK1/2. Interestingly, we observed again up-
regulation of pAKT levels after treatment with SCH772984
in M398, M376, M397AR, M249AR4, and M409AR1, sug-
gesting a rapid upregulation of the PI3K/AKT/mTOR path-
way. This suggests that dual inhibition with SCH772984
and an AKT or mTOR inhibitor may result in more potent
Figure 4 SCH722984 in BRAF-mutant melanoma cell lines with vemurafenib-acquired resistance. A. IC50 (nM) to SCH-722984 or
vemurafenib. M398 and M376, two melanoma cell lines established from tumors progressing on vemurafenib, as well as six parental BRAF mutant
melanoma cell lines and their paired in vitro derived vemurafenib-acquired resistance sublines (AR) were grown in the presence of 0–10 μM
SCH-722984 (black bars) or vemurafenib (grey bars). Values are mean of three experiments, performed in duplicate (n = 6). Error bars are standard
deviation. Bar at 1 μM denotes threshold between sensitive and intermediate. Resistant cell lines have IC50 higher than 2 μM. *: BRAF/NRAS
double mutant, **: BRAF-splice variant, §: Receptor tyrosine kinase upreguation, +: resistance mechanism unknown. B. Effect of SCH722984 on
MAPK signaling. Western blot analysis was performed to evaluate the effect of 24 hour exposure to 500 nM SCH&22984 (+) or DMSO (−) on
phospho- or total MEK, ERK 1/2, RSK, AKT or beta-actin as loading control.
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disappearance of pERK was robust. In contrast, for the
resistant M229AR9, M238AR2 and M409AR1, though
treatment with SCH772984 resulted in disappearance
of pRSK, pMEK appeared to be induced and pERK1/2
remained almost unchanged (Figure 4B).Synergistic inhibition with combination BRAF and
ERK inhibition
We next determined whether combining BRAF and ERK
inhibition could result in synergistic inhibition by dual
MAPK pathway inhibition. Treatment of M238 and M792,
two BRAFV600E-mutant melanoma cell lines highly sensitive
Wong et al. Molecular Cancer 2014, 13:194 Page 8 of 15
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with equimolar concentrations of combined vemurafenib
and SCH772984 treatment resulted in potent synergistic
growth inhibition with IC50 of 10nM (Figure 5A, 5B).
Combining vemurafenib with SCH772984 resulted in a
more profound decrease in pRSK and pERK for the
highly sensitive M262 and M792 lines compared to un-
treated controls or treatment with either agent alone.
M262 resulted in decreased pAKT levels after all three
treatments. For M308, which is resistant to vemurafenib
and sensitive to SCH772984, as pRSK was already com-
pletely absent with treatment with SCH772984 alone,
no additional effect of the combination was apparent
(Figure 5C). Interestingly, at 24 hours post treatment,
induction of pMEK and pERK was already seen, indicat-
ing rapid feedback recovery for M308, despite its sensi-
tivity to SCH772984. A slight decrease in pERK1/2 was
seen with SCH772984 treatment, with a compensatory
increase in pMEK. The generally more resistant M308Figure 5 Susceptibility of BRAF mutant melanoma cell lines to MAPK
120 hours treatment with 0–10 μM vemurafenib (V, squares), SCH722984 (E
determined by bioluminescence assay. Results are representative data in du
BRAF-, ERK- inhibition or the combination on MAPK signaling. Cell lines we
nM SCH722984 (ERKi, E) or the combination of vemurafenib and SCH72298
MEK, ERK1/2, RSK, AKT and actin as loading control. D. IC50 (nM) to MAPK in
treated with 0–10 μM vemurafenib (BRAFi) or SCH722984 (ERKi), the combi
yellow intermediately sensitive, and red for resistant. The CI column indicatand M370 lines, in contrast to the generally more sensitive
M262 and M792 lines, did not show a decrease in pMEK
when combining the two drugs, which seems to be due to
the lack of activity of vemurafenib in these resistant cells.
No additive effect from the dual upstream blockade could
be noticed in the immediate downstream targets, indi-
cating that the pathway remained active (Figure 5C). All
cell lines sensitive to BRAFi were also sensitive to the
combination. Four intermediately sensitive cell lines to
BRAFi became highly sensitive to the combination, with
improved pathway inhibition compared to ERK inhibition
alone in all cases. More importantly, highly resistant cell
lines to BRAFi became sensitive (M420, M308, M410) or
intermediately sensitive (M417, M370, M229AR, M409AR1)
to the combination. Three remained resistant but with a
slightly improved IC50. C.I.s demonstrated synergy with
combined BRAF and ERK inhibition for all cell lines ex-
cept M308, in which dual treatment with vemurafenib
and SCH772984 is only additive (Figure 5D).inhibitors. Percent growth inhibition of (A) M238 and (B) M792. After
, circles), or the combination (V + E, triangles), cell viability was
plicate from three independent experiments (n = 6). C. Effect of
re treated with DMSO (control, C), 500 nM Vemurafenib (BRAFi, B), 500
4 (B + E) for 24 hours. Western blots analyzed for phospho- and total
hibitors and synergistic effect. BRAF-mutant melanoma cell lines were
nation (B + E) or 0–1 μM trametinib (MEKi). Green indicates sensitivity,
es the combination index of vemurafenib and SCH722984.
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BRAFi could be sensitive to a MEK inhibitor (MEKi) or
ERKi. Sensitivity of BRAF mutant melanoma cell lines to
BRAFi predicted sensitivity to MEK and ERK inhibitors.
Furthermore, 10 cell lines inherently resistant to BRAFi
were often sensitive to MEK and ERK inhibition, and cell
lines resistant to BRAFi or MEKi were relatively more sen-
sitive to SCH722984. Indeed, combining BRAF with ERK
inhibition potently decreased the equimolar IC50 of all cell
lines and resulted in synergy in all but one case (M308), in-
cluding M255, M399 and M420, which are completely re-
sistant to individual inhibitors (Figure 5D). Because the
combination on BRAF combined with MEK inhibition is
currently FDA approved for BRAFV600 mutant melanoma,
we also determined the IC50 for the combination of
vemurafenib and trametinib. The results showed potent
growth inhibition and synergy in all cell lines. Sensitivity to
the vemurafenib + trametinib combination generally over-
lapped with sensitivity to the vemurafenib + SCH722984
combination (Figure 5D), consistent with the idea that both
combinations cause dual MAPK blockade. The growth
curves for the vemurafenib + trametinib combinations are
shown in Additional file 5: Figure S5.
Effects of MAPK pathway inhibition on cell cycle
progression and apoptosis
To determine the effect of BRAF or ERK inhibition on cell
cycle progression and apoptosis, cells were treated with
SCH772984, alone or in combination with vemurafenib
for 48 hours then stained with DAPI and intracellularly
for cleaved PARP and analyzed by flow cytometry. Treat-
ment with either of these two inhibitors resulted in an
increase in the sub-G0 population, the G1 population, as
well as an increase in cleaved PARP levels which indicates
apoptotic cells (Figure 6A). A modest increase of 3-10%
was seen in the sub-G0 population for all cell lines treated
with vemurafenib, SCH772984 or the combination. The
amount of subG1 increase did not correlate with sensi-
tivity or resistance to the MAPK pathway inhibitors. In
contrast, for the G0-G1 populations, there was a correl-
ation with sensitivity, with an up to 40% increase in G0-
G1 population seen in the sensitive cell lines M238 and
M792, while the resistant cell lines M233 and M299
demonstrated only a 10% increase in the G0-G1 popula-
tion for the combination treatment. Concomitant with
the increase in G0-G1, a decreased proportion of cells
were observed in S-phase, with the largest decreases of
over 20% seen in the sensitive cell lines M792 and M238
(Figure 6B). Treatment of the sensitive cell lines, M238
and M792, with SCH772984 alone or in combination with
vemurafenib resulted in a dramatic increase in cleaved
PARP reaching induced percentages around 40-50%. In
comparison, the resistant cell lines (M233 and M299) had
cleaved PARP at 20-25% (Figure 6C). With the exceptionof M299, a statistically significant increase in cleaved PARP
was seen in all cell lines treated with SCH772984, or the
combination of SCH772984 and vemurafenib, compared to
vemurafenib alone. Combinatorial treatment offered a sta-
tistically significant increase in cleaved PARP compared to
vemurafenib alone in all cell lines (20% increase in sensitive
cell lines and 10% increase in resistant cell lines compared
to vemurafenib alone). However only a trend towards in-
creased cleaved PARP fractions was observed comparing
combinatorial treatment with SCH772984 alone without
reaching statistical significance.
To address whether there are differences in MEK in-
hibition or ERK inhibition on apoptosis, we performed
cell cycle analysis on three melanoma cell lines with dis-
tinct sensitivity profile to SCH772984: M263 (sensitive),
M255 (intermediately sensitive) and M370 (resistant).
All three cell lines demonstrated good synergy for the
combination of vemurafenib and SCH772984. Cell
lines treated with SCH772984 or the combination of
vemurafenib + SCH772984 had the highest levels of
cleaved PARP. In comparison, trametinib, did not induce
the same levels of apoptosis in any case. In terms of
effects on the cell cycle, G0-G1 arrest was maximally
induced by ERK inhibition also (Additional file 6:
Figure S6). This data support the potent activity of
SCH772984 both as a single agent and in combination.
Combining BRAF and ERK inhibition delays the
development of resistance
Given the potent synergistic inhibition seen when com-
bining vemurafenib and SCH772984, we hypothesized
that chronic exposure to dual inhibition would signifi-
cantly delay the development of resistance compared to
either single agent alone. To test this hypothesis, long
term cultures were established in 96-well plates to allow
both qualitative and quantitative assessment of the effect
of each drug alone or their combination on M238 and
M792, which are highly sensitive to both inhibitors and
for which dual therapy was highly synergistic (Figure 7A).
Treatment with 500nM vemurafenib initially suppressed
growth of M238 and M792, however, by 42 days of treat-
ment, several wells were confluent and cells had normal
morphology, indicating development of BRAFi-resistance.
In contrast, very few cells were seen in plates treated with
ERKi alone or in combination at 42 days (Figure 7B). For
ERKi-treated M792 plates, confluent wells were not seen
until 84 days. When cell viability was quantified at day 44
for BRAFi-treated cells, over 90% of the wells had >10,000
viable cells. In contrast, many fewer viable cells were seen
for M792 treated with ERKi alone or in combination with
BRAFi measured at day 84. Only 20% of the wells treated
with ERKi alone and <5% of wells treated with the com-
bination had >10,000 cells (Figure 7C). For M238, similar
data were seen, though in this case, treatment with 500nM
Figure 6 Effect of SCH722984, vemurafenib or the combination on cell cycle progression and apoptosis in BRAF-mutant melanoma
cell lines. Two sensitive cell lines (M238 and M792) and two resistant cell lines (M233 and M299) were exposed to DMSO as vehicle control
(Unst, control unstained: Control, control stained), 1 μM vemurafenib (Vem), SCH722984 (ERKi), the combination (V + E) or 1 μM staurosporine
for 48 hours. A. Cell cycle progression was tested by DAPI staining solution and induced apoptosis by cleaved PARP (PARP-Ax700). Figures are
representative of triplicate experiments. B. Quantitative analysis of the cell cycle progression by DAPI staining using flow cytometry shows the
percentage of cells in sub-G0 (blue), G0/G1 (red), S phase (yellow), or G2/M (green). Numbers on the bar graph represent percentage of cells in
G0/G1. Columns represent mean values of three independent experiments (n = 3); bars, SEM. C. Apoptosis in response to MAPK inhibitors.
Percentage of apoptotic cells positive for cleaved PARP (PARP-Ax700) in this four melanoma cell lines. Columns represent mean values of three
independent experiments (n = 3); bars, SEM; *, P < 0.05.
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140 days. Most strikingly, for M238, 280 days, twice that
for SCH772984 alone, were required for resistance to the
combination of vemurafenib and SCH772984 to develop
(Figure 7D). Taken together, these data provide preliminary
in vitro evidence that SCH772984 may more potently and
more durably inhibit BRAF-mutant melanoma compared
to single agent vemurafenib, and that the combination
of BRAF and ERK inhibition results in better inhibition
than either alone. These data are intriguing and should
be further validated in vivo.
Discussion
Our work reports the potent activity of SCH772984
against a large panel of well-characterized melanoma celllines. SCH772984 is highly active amongst BRAF-mutant,
NRAS-mutant, double mutant and double wild-type mel-
anoma cell lines, and this drug potently inhibited some
lines with innate resistance or acquired resistance to
vemurafenib. The efficacy of SCH772984 in NRAS-mutant
and double wild-type melanoma was also striking with the
majority being highly sensitive.
Previously published reports have documented promising
preclinical activity of ERK inhibition in BRAFi or MEKi
resistant cell line models [30,32,33]. Our data are consist-
ent with the work of Carlino et al., who demonstrated that
SCH772984 induced cell death for all sensitive cell lines.
SCH772984 also resulted in growth inhibition of only
melanoma cell lines with MAPK-dependent mechanisms
of BRAFi-resistance, and not those with RTK upregulation
Figure 7 Effect of combined MAPK inhibition on long-term melanoma cultures. M238 and M792, two MAPK inhibitor-sensitive cell lines,
were chronically exposed to 500nM of Vemurafenib (V), SCH722984 (E) or combination (V + E) in 96-well plates. A. Schematic. For each cell line,
20,000 cells/well were plated on 96-well plates. The following day, all cells on the plate were treated with 500nM of each drug or combination.
Fresh media containing the appropriate inhibitor(s) was added weekly. When cells in several wells were confluent, viable cells were quantified by
MTS assay and cell numbers were determined by comparing with a standard curve of known cell numbers. B. Microscopic imaging of treated
M238 cells photographed at 14 days (top) or 44 days (bottom) of treatment. C. Quantitative analysis of viable cells for M792 at 44 days (V) or
84 days (E and V + E). D. Quantitative analysis of viable cells for M238 at 44 days (V), 140 days (E) or 280 days (V + E). The percentage of wells with
1–1,000 (white), 2,000-3,999 (tan), 4,000-5,999 (yellow), 6,000-7,999 (orange), 8,000-9,999 (red) and >10,000 (brown) viable cells are shown. Data are
representative of triplicate independent experiments.
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work demonstrated that trametinib less completely inhib-
ited MAPK signaling compared to inhibition with VX-11e,
an ERKi tool compound [33]. Since resistance to BRAFi
or MEKi is highly dominated by the reactivation of the
MAPK pathway (acquisition of RAS mutations, BRAFV600
amplifications, MEK mutations, BRAFV600E amplification
or the Δ2-8 BRAF splice variant [30] or secondary RTK
overexpression), SCH772984 is a promising strategy to
delay or revert resistance and has demonstrated activity in
our BRAFi-resistant melanoma cell lines with reactivation
of the MAPK pathway mechanism of resistance. Unfortu-
nately resistance to SCH772984 may appear and resistance
mechanisms will likely differ from those characterized thus
far. We observed that increased pAKT levels at baseline
levels were tightly correlated with intrinsic resistance toSCH772984 in the BRAF- mutant melanoma cell lines.
Little to no pAKT activity was found in two NRAS mu-
tant or two double wild type cell lines. Indeed, Carlino
et al. hypothesize consistently in their work that pAKT
levels for BRAF mutant melanoma cells may play a key
role in resistance. SCH772984 is unique, having both
ATP-competitive and non-competitive properties, lead-
ing to suppression of both the downstream factors of
and pERK1/2 itself which was observed in short term
treatment (less than 12 hours) of cell lines tested in this
study. This was further elucidated by Morris et al., who
demonstrated that the inhibition of pERK1/2 is not just
mediated by inhibitor binding to MEK. Instead, they
hypothesize that binding of SCH772984 to ERK protein not
only prevents ATP binding and therefore phosphorylation
of downstream targets like RSK, but that ERK binding
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phosphorylate ERK1 at threonine 202/tyrosine 204 and
ERK2 at threonine 185/tyrosine 187 [30]. Additionally,
the data herein underscore the importance of MAPK
feedback loops in sensitivity to SCH772984 given the
consistent finding that cell lines resistant to SCH772984
are able to rapidly recover pMEK and pERK activity, while
those sensitive to SCH772984 have delayed ability to do so.
One notable exception to this signaling pattern is M308,
which demonstrated a rapid recovery of MAPK activity
even at 24 hours after ERKi-treatment, despite its sensi-
tivity to SCH772984. In work ongoing in the lab, among
5 BRAF-mutant cell lines sensitive to SCH772984, M308
was the only cell line to develop resistant subclones
after 2 months of chronic exposure to SCH772984
(data not shown). This indicates that feedback recovery
may be an important predictor of development of ac-
quired resistance to ERKi. Given that pRSK remains
suppressed at all time points tested, reactivation of the
MAPK pathway may allow signaling through other ERK
downstream targets, such as cyclin D1.
Previous data supports that pERK signaling recovers rap-
idly after vemurafenib treatment, yet cells remain growth
arrested [16]. Besides the synergistic effect of vemurafenib
and SCH772984, our data supports a strong induction of
apoptosis with the ERKi compared to the BRAFi alone.
This should encourage combined therapy approaches to
strengthen the therapy against feedback loops reactivated
after single point blockade. The strategic aspect of ERK in-
hibition both blocking downstream in the MAPK pathway
and blocking the cross-talk with Pi3K/AKT can support a
rationale to combine inhibition of both pathways.
Both the non-competitive inhibitory properties of
SCH772984 and its ability to cause reactivation of the
MAPK pathway may explain the synergy seen with com-
bination BRAF- and ERK-inhibition in the vast majority
of BRAF-mutant melanoma. It may also explain the dra-
matic delay in development of resistance seen with
BRAF-inhibitor in BRAF-mutant melanoma tested in
this study. At first glance, the idea of inhibiting two
points in the same pathway may seem redundant. However,
as shown herein, the dual inhibition approach may be a
good strategy to control the feedback loop reactivation that
occurs with singular treatment with ERKi. Carlino et al.
[33] , recently published that combinatorial blockade with
relatively high concentrations of the ERKi, Vx-11e (10 μM)
and PI3K/AKT inhibitor BEZ235 (2 μM) more completely
induced cell death in BRAF-inhibitor resistance melanoma
cell lines compared to the combination of trametinib
(10nM) and BEZ235. Consistent with this, Lassen et al. re-
cently demonstrated that MAPK and PI3K pathway dual
inhibition can effectively inhibit melanoma cells [34]. Given
the likely differences in toxicity profile of both combinator-
ial approaches, clinical evaluation of both BRAFi/ERKi andERKi/PI3Ki should be pursued. Further investigations
regarding the mechanisms underlying both primary and
acquired resistance to SCH772984 are ongoing.
Conclusions
Currently, at least two ERK inhibitors are in phase I
studies, including MK8353, a clinical grade analog of
SCH772984, and BVD-523. Our preclinical findings
demonstrate the ability of SCH772984 to inhibit the
majority of melanoma cell lines tested. Over 50% of all
melanoma patients are non-BRAF mutated, with NRAS-
mutant and double wild-type comprising 15-20% and 40%
of melanoma patients, respectively. As there are currently
no FDA-approved targeted therapies for these non-BRAF
mutated melanoma, these data provide intriguing pre-
clinical basis for further development and testing of
ERK inhibitors for these melanoma subtypes, as well as
for combinatorial therapy with BRAF and ERK inhibitors
in BRAF-mutant melanoma. Therefore, ERK inhibitors
hold much promise to augment the armamentarium of
effective targeted therapies for melanoma, regardless of
BRAF mutational status and irrespective of sensitivity to
BRAF inhibitors.
Materials and methods
Reagents and cell lines
SCH722984 (Erk inhibitor), MK-2206 (AKT inhibitor)
and MK-8669 (mTOR inhibitor) were obtained through
a materials transfer agreement with Merck Sharp & Dohme
Corp. (Whitehouse Station, New Jersey). Vemurafenib
and trametinib were commercially purchased (Selleck
Chemicals, Houston, TX). All drugs were reconstituted in
100% dimethyl sulfoxide (DMSO) to a final concentration
of 10 mM. With the exception of Sbcl2, SKMel173,
WM1366, which were obtained from Dr. Roger S. Lo
(UCLA), all other human melanoma cell lines were
established from patient biopsies under UCLA- IRB #02–
08-067, as previously described [31]. Cells were cultured in
RPMI 1640 with L-glutamine (Mediatech, Inc, Manassas,
VA), 10% fetal bovine serum (FBS, Omega Scientific,
Tarzana, CA), and 1% penicillin, streptomycin and fungizone
(PSF, Omega Scientific). Cultures were incubated in a water-
saturated incubator at 37°C with 5% CO2.
Cell viability
All cell lines were treated in duplicates with 0–10 μM
of SCH722984, vemurafenib and trametinib alone or in
combination and constant amount of DMSO for all the
conditions. After incubation for 72–120 hours, the cell
viability was determined using CellTiter-Glo Luminescent
Cell Viability Assay (Promega, Madison, WI), an ATP-
based bioluminescent assay, as per manufacturer’s
instructions. Each experiment was repeated independently
at least 3 times.
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cell lines were plated at 20,000 cells per well in 96-well
plates and chronically exposed to 500nM of vemurafenib,
SCH722984 or the combination. Cells were re-fed with
fresh media containing the appropriate inhibitor(s)
weekly. Pictures were taken weekly to document visual
differences in between conditions. Plates were considered
for cell viability reading with [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) (Promega) as previously described [31] when several
wells appeared visually to be >90% confluent. The number
of viable cells in each well was determined based on a
standard curve of known cell numbers. Each condition
was repeated in triplicate independent experiments.
Western blotting
All melanoma cells were washed with ice-cold phos-
phate buffered saline (PBS) twice and lysed with RIPA
buffer containing phosphatase and protease inhibitors
(all from Sigma Aldrich, St. Louis, MO). Protein extracts
were separated with SDS-PAGE in 4-12% tris-glycine gels
and transferred to immun-blot PVDF membrane. After
blocking for 1 hour in PBS containing 0.1% Tween 20
and 5% nonfat milk or 5% bovine serum albumin (BSA)
in PBS, the membrane was exposed to various primary
antibodies overnight, followed by secondary antibodies
conjugated to horseradish peroxidase. ECL-Plus kit
(Amersham Biosciences Co, Piscataway, NJ) was used
to check immunoreactivity and blots were scanned
using a Typhoon scanner (Amersham Biosciences Co.).
Primary antibodies included pERK Thr202/Tyr204, total
ERK, pMEK Ser217/221, total MEK, pAKT Ser473, total
AKT, pRSK, total RSK, beta-actin (all from Cell Signaling
Technology, Danvers, MA).
Cell-cycle analysis and assessment of apoptosis by
flow cytometry
M238, M792, M299 and M233 melanoma cell lines were
incubated with 1 μM of DMSO as vehicle control, vemur-
afenib, SCH772984, or the combination for 48 hours. Cells
were collected and fixed with BD Cytofix/Cytoperm
(BD Biosciences, San Jose, CA), washed with BD Perm/
Wash Buffer 1x and resuspended in 500 μL of 4,6-
diamidino-2-phenylindole (DAPI) solution at a final
concentration of 2 mg/mL, 0.001% Nonident P-40, and
1% BSA in PBS (Sigma-Aldrich). Analysis was performed
after acquiring 12,000 cellular events in G0-G1 gate per
sample. For analysis of apoptosis, cells were checked at
the level of cleaved poly [ADP-ribose] polymerase (PARP).
After fixation and permeabilization as described above,
cells were stained with anti–PARP-Alexafluor700 antibody
(clone F21-852; BD Biosciences). A minimum of 12,000
cellular events per sample were collected by flow cytome-
try. All flow cytometry experiments were carried out usingan LSRII (BD Biosciences), using biexponential axes. Data
were analyzed using FlowJo (Tree Star, Inc, Ashland, OR).
Statistical analysis
Data analysis was performed with Microsoft Excel and
GraphPad Prism to determine the 50% inhibition concen-
tration (IC50). Synergistic, additive or antagonistic effects of
drug combinations were determined using Calcusyn soft-
ware (version 2.0, Biosoft, Cambridge, United Kingdom)
to determine the combination indices (C.I.) as previously
described [35], where synergy is defined as C.I. <1, ad-
ditivity C.I. ≃ 1, and antagonism is C.I. >1.
Additional files
Additional file 1: Figure S1. Effect of trametinib on BRAF mutant
melanoma cell lines. IC50 (nM). Ninteen BRAF mutant melanoma cell lines were
exposed to 0–1 μM trametinib and cell viability determined by ATP-based
bioluminescence assay (CellTiter-Glo, Promega). Results represent mean of
duplicate assay performed in three independent experiments.
Additional file 2: Figure S2. Levels of pAKT across a group of BRAF,
NRAS and double wild-type melanoma cell lines. 8 BRAF-mutant, 2
NRAS-mutant and 2 wild type melanoma cell lines in order of increasing
IC50 sensitivities to SCH772984 were evaluated by Western Blot analysis
for baseline pAKT levels.
Additional file 3: Figure S3. Effects of SCH722984 combined with
MK-2206 (AKT inhibitor) and MK-8669 (mTOR inhibitor) in BRAF mutant
cell lines. A. IC50s of SCH722984 alone or in combination with MK-2206 or
MK-8669. After 120 hours treatment with 0–10 μM SCH722984,
SCH722984+ MK-2206 or SCH722984+ MK-8669, cell viability was
determined by bioluminescence assay. Results are representative data in
duplicate from three independent experiments (n = 6). B. Percent growth
inhibition for two BRAF-mutant melanoma cell lines (M233 and M411)
and two NRAS-mutant cell lines (M409 and WM1366). After 120 hours
treatment with 0–10 μM SCH772984 + MK2206 (ERKi + AKTi, squares),
SCH722984 + MK-8669 (ERKi + mTORi, triangles), or the SCH772984
(ERKi, circles), cell viability was determined by bioluminescence assay.
Results are representative data in duplicate from three independent
experiments (n = 6). C. Effect ERK- inhibition alone or the combination
with AKT/mTOR inhibitors on MAPK signaling. Cell lines were treated with
DMSO (control, C), 1 uM SCH722984 (ERKi, E) or the combination of
SCH722984+ MK-2206 and SCH722984+ MK-8669 at 1 uM for 24 hours.
Western blots analyzed for phospho- and total ERK1/2, AKT and actin as
loading control.
Additional file 4: Figure S4. Effect of trametinib on NRAS mutant and
double wild type cell lines. IC50 (nM). 14 NRAS mutant and 7 double
wild-type melanoma cell lines were exposed to 0-1 μM trametinib and
cell viability was determined by ATP-based bioluminescence assay
(CellTiter-Glo, Promega). Results represent mean of duplicate assay
performed in three independent experiments.
Additional file 5: Figure S5. Combinatorial effect of Vemurafenib with
SCH772984 or Trametinib. Percent growth inhibition of BRAF mutant cell
lines. After 120 hours treatment with 0–10 μM vemurafenib (squares)
combined with 0-10 uM SCH722984 (circles), or 0–10 μM vemurafenib
combined with 0-1 μM trametinib, cell viability was determined by
bioluminescence assay. Results are representative data in duplicate from
two independent experiments (n = 6).
Additional file 6: Figure S6. Effect of SCH722984, vemurafenib or the
combination on cell cycle progression and apoptosis in BRAF-mutant
melanoma cell lines. A sensitive cell line (M263), intermediate sensitivity
(M255) and resistant to SCH722984 (M370) were exposed to DMSO as
vehicle control (ControL), 1 μM vemurafenib (Vemurafenib), SCH722984
(ERKi), 50nM trametinib (Trametinib), the combination of 1 μM vemurafenib
+ 1 μM SCH722984 (V + E) or the combination of 1μMvemurafenib + 50nM
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was tested by DAPI staining solution and induced apoptosis by cleaved
PARP (PARP-Ax700). B. Apoptosis in response to MAPK inhibitors. Percentage
of apoptotic cells positive for cleaved PARP (PARP-Ax700) in this three
melanoma cell lines. B. Quantitative analysis of the cell cycle progression by
DAPI staining using flow cytometry shows the percentage of cells in
sub-G0, G0/G1, S phase, or G2/M.
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